Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Longitudinal Increases in Adiposity Contribute to Worsening Adipokine Profile over Time in Mexican Americans

Black MH., Shu YH., Wu J., Koebnick C., MacKay A., Watanabe RM.

Prospective Study on Type 2 Diabetes, Chronic Inflammation, published in Obesity (Silver Spring) (2018) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Obesity (Silver Spring) (2018)
Reported sample size
—
Source database
Europe PMC
PMID
29427376
PMCID
PMC6021026
DOI
10.1002/oby.22128
Citations
12

Abstract (original English)

Objective Limited studies have assessed the relationship between longitudinal changes in adiposity and changes in multiple adipokines over time. This study examined changes in BMI, total body fat, and trunk fat associated with changes in 16 circulating adipokines in Mexican Americans at risk for type 2 diabetes. Methods Participants included 1,213 individuals with cross-sectional data and a subset of 368 individuals with follow-up measures (mean 4.6 ± 1.5 years from baseline). Joint multivariate associations between 3 adiposity measures and 16 adipokines were assessed by canonical correlation analysis. Results Longitudinal increases in adiposity were most strongly associated with increasing leptin, C-reactive protein (CRP), and interleukin 1 receptor antagonist (IL-1Ra) and decreasing adiponectin and secreted frizzled protein 5 (SFRP5) over time. Participants with BMI ≥ 30 kg/m 2 at baseline had greater increases in leptin, CRP, IL-1Ra, and interleukin 6 (IL-6) and greater decreases in adiponectin and SFRP5, associated with increasing adiposity over follow-up, than those with BMI 2 . Associations between adiposity and adipokines were most accounted for by leptin; adjustment for leptin greatly reduced the magnitude of all associations between adiposity and remaining adipokines. Conclusions Increasing adiposity contributes to a worsening imbalance of pro- and anti-inflammatory ad

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansDiabetes Mellitus, Type 2LeptinC-Reactive ProteinInterleukin-6AdultMexican AmericansFemaleMaleAdiposity

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research